A Phase 3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults with Active Sj gren s Syndrome (POETYK-SjS-1)

Go Back to All Clinical Trials

A Phase 3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults with Active Sj gren s Syndrome (POETYK-SjS-1)

Brief description of study

This is the first time deucravacitinib is being studied in people with Sjogren’s Syndrome. By doing this study, researchers hope to learn more about whether deucravacitinib can help in the treatment of Sjogren’s Syndrome (SjS) and how safe it is to use in participants with active SjS. Deucravacitinib is an experimental drug, which means its safety and effectiveness have not been established and it has not been approved by the United States Food and Drug Administration (FDA) for the treatment of SjS. Placebo for deucravacitinib treatment consists of a pill that looks like the study drug but does not contain any active study drug.

Clinical Study Identifier: s23-00706

ClinicalTrials.gov Identifier: NCT05946941

Principal Investigator: Steven E Carsons.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies